GLOBAL HUMAN GROWTH HORMONE MARKET FORECAST 2023-2032

SCOPE OF THE REPORT

Global Human Growth Hormone Market by Application (Growth Hormone Deficiency, Prader-willi Syndrome, Turner Syndrome, Small for Gestational Age, Other Applications) Market by Route of Administration (Oral, Intravenous, Intramuscular, Subcutaneous) Market by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) by Geography


MARKET OVERVIEW

In terms of revenue, the global human growth hormone market was valued at $xx million in 2022 and is expected to reach $xx million by 2032, growing at a CAGR of 8.56% during the forecast period 2023-2032

Human growth hormone (HGH), also known as somatotropin, is a hormone that the pituitary gland naturally produces in the human body. It is essential in various physiological processes, including growth and development. HGH boosts bone, muscle, and organ growth during childhood and adolescence. Moreover, the hormone assists in cell regeneration and repair, ensuring proper tissue growth. HGH also helps to regulate bodily fluids and metabolism and influences factors, including muscle mass, bone density, and fat distribution.

HGH production peaks during childhood and then gradually falls with age. Synthetic variants of HGH have been produced and are employed in medical therapies for specific ailments. These variants are provided through injections and imitate the functions of natural HGH.

Human Growth Hormone Market

Read our latest blog on the Human Growth Hormone Market

GROWTH ENABLERS

Key growth enablers of the global human growth hormone market:

  • Prevalence of pituitary dysfunction cases
  • Awareness of growth hormone therapy’s benefits
  • Off-label usage of human growth hormone
  • Growth hormone deficiency in the aging population
    • The global aging population has been a major driving force in the global human growth hormone market. 
    • Growth hormone levels naturally fall with age, and individuals may suffer from growth hormone shortages as they grow older. Moreover, as per World Health Organization (WHO), in 2020, 1 billion people were aged above 60 years.
    • In 2020, the Food and Drug Administration (FDA) approved Sogroya (somapacitan) for adults with growth hormone insufficiency. Sogroya is the first human growth hormone (HGH) medication that adult patients receive once a week via subcutaneous injection.

GROWTH RESTRAINTS

Key growth restraining factors of the global human growth hormone market:
  • High cost of human growth hormone therapy
  • Side effects 
  • Stringent government regulations
    • Human growth hormone therapy has been linked to a number of hazards and adverse effects, including joint pain and swelling, as well as an increased risk of diabetes and cancer. As a result, several countries have imposed stringent government limitations on the use of human growth hormone therapy.
    • The FDA regulates human growth hormone (HGH) to ensure that it is safe and effective for permitted purposes. Clinical trials are also required by the FDA for HGH manufacturers to demonstrate the safety and efficacy of their products. Furthermore, in order to maintain the quality of HGH products, the FDA also requires producers to adhere to strict production requirements.
To Know More About This Report, Request a Free Sample Copy

KEY MARKET TRENDS

Global Human Growth Hormone Market | Top Trends

  • The rising expenditure in research and development activities aimed at generating new growth hormone products and expanding their therapeutic applications is driving the expansion of the global human growth hormone market. Furthermore, the increased emphasis on precision medicine and tailored therapeutics is projected to drive market expansion in the future years.
  • Technological advancements in human growth hormone, such as the introduction of long-acting HGH formulations, have been key advancements in HGH therapy. These formulations give sustained release of HGH for a longer period of time, lowering the number of injections necessary for therapy. In turn, this increases patient compliance and convenience while also improving treatment outcomes.

MARKET SEGMENTATION

Market Segmentation – Application, Route of Administration, and Distribution Channel – 

Market by Application: 

  • Growth Hormone Deficiency
  • Prader-Willi Syndrome (PWS)
    • The benefits of HGH therapy for PWS are becoming better recognized. In persons with PWS, HGH therapy has been found to improve growth, body composition, and physical function.
    • There has been improved access to HGH therapy in recent years. In the past, HGH therapy was expensive and not widely available. However, the cost of HGH therapy has declined over the years and is now more widely available.
    • PWS treatment alternatives are also observing increasing demand. As a complicated illness with no known cure, HGH therapy can assist persons with PWS in improving their quality of life.
  • Turner Syndrome
  • Small for Gestational Age
  • Other Applications

Market by Route of Administration:

  • Oral
  • Intravenous
  • Intramuscular
  • Subcutaneous
    • Subcutaneous is set to be the prominent route of administration during the forecast period. 
    • HGH is a large protein molecule that is broken down by the digestive system when taken orally, making it difficult for the hormone to be absorbed into the bloodstream adequately.
    • Subcutaneous injections are the most popular and successful technique for giving HGH. The hormone is injected directly into the fatty tissue beneath the skin, allowing for rapid absorption into the bloodstream.
    • These injections are generally simple and quick to administrate, allowing for convenient self-administration by individuals who have been instructed by healthcare experts. This removes the need for frequent clinic visits.

Market by Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

GEOGRAPHICAL STUDY

Geographical Study Based on Four Major Regions: 

  • North America: The United States and Canada
    • North America is the major region in the global human growth hormone market. 
    • Increased research and development activities, advantageous reimbursement policies, established healthcare infrastructure, considerable government initiatives, and increased healthcare awareness are the main forces driving market expansion in the United States.
    • In the United States, recombinant growth hormone is largely utilized for the treatment of gestational age or intrauterine growth retardation, growth hormone deficiency (GHD), Prader-Willi syndrome, Turner’s syndrome, chronic renal insufficiency, as well as cachexia. The United States also accounts for the majority number of patients with Turner syndrome due to factors like the increasing female population. 
    • Furthermore, rising awareness of growth hormone deficiency and treatments is projected to drive market growth. Every year, for example, the International Coalition of Organizations Supporting Endocrine Patients (ICOSEP) observes Children’s Growth Awareness Day to raise awareness about the early detection and treatment of growth hormone abnormalities.
  • Europe: The United Kingdom, France, Germany, Spain, Italy, Poland, Belgium, and Rest of Europe
  • Asia-Pacific: China, Japan, India, South Korea, Indonesia, Thailand, Vietnam, Australia & New Zealand, and Rest of Asia-Pacific

Rest of World: Latin America, the Middle East & Africa

MAJOR PLAYERS

Major players in the global human growth hormone market:

  • AnkeBio Co Ltd
  • Eli Lilly and Company
  • Ferring BV
  • Novo Nordisk AS
  • Ispen SA 

Key strategies adopted by some of these companies:

  • In February 2021, Pfizer Inc began Phase III clinical research in order to assess the safety and efficacy of somatropin in a group of Japanese Prader-Willi Syndrome (PWS) patients.
  • In October 2020, Erasmus Medical Center, in collaboration with Pfizer, the Foundation for Prader-Willi Research, and the Prader-Willi Fonds, launched a Phase III clinical trial in order to assess the impact of growth hormone treatment (Genotropin) on psychosocial as well as physical health in adults with Prader-Willi syndrome aged 30 and up.

REPORT SYNOPSIS

REPORT SCOPEDETAILS
Market Forecast Years2023-2032
Base Year2022
Market Historical Years2018-2022
Forecast UnitsRevenue ($ Million)
Segments AnalyzedApplication, Route of Administration, and Distribution Channel
Geographies AnalyzedNorth America, Europe, Asia-Pacific, and Rest of World
Companies AnalyzedAnkeBio Co Ltd, Eli Lily and Company, Ferring Pharmaceuticals, ISPEN, LG Chem Ltd, Merc & Co Inc, Novartis International AG, Novo Nordisk AS, Pfizer Inc, Sandoz International GmbH

TABLE OF CONTENT

  1. RESEARCH SCOPE & METHODOLOGY
    1. STUDY OBJECTIVES
    2. METHODOLOGY
    3. ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    1. MARKET SIZE & ESTIMATES
    2. MARKET OVERVIEW
    3. SCOPE OF STUDY
    4. CRISIS SCENARIO ANALYSIS
    5. MAJOR MARKET FINDINGS
  3. MARKET DYNAMICS
    1. KEY DRIVERS
      1. PREVALENCE OF PITUITARY DYSFUNCTION CASES
      2. AWARENESS OF GROWTH HORMONE THERAPY’S BENEFITS
      3. OFF-LABEL USAGE OF HUMAN GROWTH HORMONE
      4. GROWTH HORMONE DEFICIENCY IN AGING POPULATION
    2. KEY RESTRAINTS
      1. HIGH COSTS OF HUMAN GROWTH HORMONE THERAPY
      2. SIDE EFFECTS 
      3. STRINGENT GOVERNMENT REGULATIONS
  4. KEY ANALYTICS
    1. KEY MARKET TRENDS
    2. PORTER’S FIVE FORCES ANALYSIS
      1. BUYERS POWER
      2. SUPPLIERS POWER
      3. SUBSTITUTION
      4. NEW ENTRANTS
      5. INDUSTRY RIVALRY
    3. GROWTH PROSPECT MAPPING
      1. GROWTH PROSPECT MAPPING FOR UNITED STATES
      2. GROWTH PROSPECT MAPPING FOR GERMANY
      3. GROWTH PROSPECT MAPPING FOR SOUTH KOREA
      4. GROWTH PROSPECT MAPPING FOR SOUTH AFRICA
    4. MARKET MATURITY ANALYSIS
    5. MARKET CONCENTRATION ANALYSIS
  5. MARKET BY APPLICATION
    1. GROWTH HORMONE DEFICIENCY
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    2. PRADER-WILLI SYNDROME
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    3. TURNER SYNDROME
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    4. SMALL FOR GESTATIONAL AGE (SGA)
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    5. OTHER APPLICATIONS
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
  6. MARKET BY ROUTE OF ADMINISTRATION
    1. ORAL
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    2. INTRAVENOUS
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    3. INTRAMUSCULAR
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    4. SUBCUTANEOUS
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
  7. MARKET BY DISTRIBUTION CHANNEL
    1. HOSPITAL PHARMACY
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    2. RETAIL PHARMACY
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    3. ONLINE PHARMACY
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
  8. GEOGRAPHICAL ANALYSIS
    1. NORTH AMERICA
      1. MARKET SIZE & ESTIMATES
      2. NORTH AMERICA HUMAN GROWTH HORMONE MARKET DRIVERS
      3. NORTH AMERICA HUMAN GROWTH HORMONE MARKET CHALLENGES
      4. NORTH AMERICA HUMAN GROWTH HORMONE MARKET REGULATORY FRAMEWORK
      5. KEY PLAYERS IN NORTH AMERICA HUMAN GROWTH HORMONE MARKET
      6. COUNTRY ANALYSIS
        1. UNITED STATES
          1. UNITED STATES HUMAN GROWTH HORMONE MARKET SIZE & OPPORTUNITIES
        2. CANADA
          1. CANADA HUMAN GROWTH HORMONE MARKET SIZE & OPPORTUNITIES
    2. EUROPE
      1. MARKET SIZE & ESTIMATES
      2. EUROPE HUMAN GROWTH HORMONE MARKET DRIVERS
      3. EUROPE HUMAN GROWTH HORMONE MARKET CHALLENGES
      4. EUROPE HUMAN GROWTH HORMONE MARKET REGULATORY FRAMEWORK
      5. KEY PLAYERS IN EUROPE HUMAN GROWTH HORMONE MARKET
      6. COUNTRY ANALYSIS
        1. UNITED KINGDOM
          1. UNITED KINGDOM HUMAN GROWTH HORMONE MARKET SIZE & OPPORTUNITIES
        2. GERMANY
          1. GERMANY HUMAN GROWTH HORMONE MARKET SIZE & OPPORTUNITIES
        3. FRANCE
          1. FRANCE HUMAN GROWTH HORMONE MARKET SIZE & OPPORTUNITIES
        4. ITALY
          1. ITALY HUMAN GROWTH HORMONE MARKET SIZE & OPPORTUNITIES
        5. SPAIN
          1. SPAIN HUMAN GROWTH HORMONE MARKET SIZE & OPPORTUNITIES
        6. BELGIUM
          1. BELGIUM HUMAN GROWTH HORMONE MARKET SIZE & OPPORTUNITIES
        7. POLAND
          1. POLAND HUMAN GROWTH HORMONE MARKET SIZE & OPPORTUNITIES
        8. REST OF EUROPE
          1. REST OF EUROPE HUMAN GROWTH HORMONE MARKET SIZE & OPPORTUNITIES
    3. ASIA-PACIFIC
      1. MARKET SIZE & ESTIMATES
      2. ASIA-PACIFIC HUMAN GROWTH HORMONE MARKET DRIVERS
      3. ASIA-PACIFIC HUMAN GROWTH HORMONE MARKET CHALLENGES
      4. ASIA-PACIFIC HUMAN GROWTH HORMONE MARKET REGULATORY FRAMEWORK
      5. KEY PLAYERS IN ASIA-PACIFIC HUMAN GROWTH HORMONE MARKET
      6. COUNTRY ANALYSIS
        1. CHINA
          1. CHINA HUMAN GROWTH HORMONE MARKET SIZE & OPPORTUNITIES
        2. JAPAN
          1. JAPAN HUMAN GROWTH HORMONE MARKET SIZE & OPPORTUNITIES
        3. INDIA
          1. INDIA HUMAN GROWTH HORMONE MARKET SIZE & OPPORTUNITIES
        4. SOUTH KOREA
          1. SOUTH KOREA HUMAN GROWTH HORMONE MARKET SIZE & OPPORTUNITIES
        5. INDONESIA
          1. INDONESIA HUMAN GROWTH HORMONE MARKET SIZE & OPPORTUNITIES
        6. THAILAND
          1. THAILAND HUMAN GROWTH HORMONE MARKET SIZE & OPPORTUNITIES
        7. VIETNAM
          1. VIETNAM HUMAN GROWTH HORMONE MARKET SIZE & OPPORTUNITIES
        8. AUSTRALIA & NEW ZEALAND
          1. AUSTRALIA & NEW ZEALAND HUMAN GROWTH HORMONE MARKET SIZE & OPPORTUNITIES
        9. REST OF ASIA-PACIFIC
          1. REST OF ASIA-PACIFIC HUMAN GROWTH HORMONE MARKET SIZE & OPPORTUNITIES
    4. REST OF WORLD
      1. MARKET SIZE & ESTIMATES
      2. REST OF WORLD HUMAN GROWTH HORMONE MARKET DRIVERS
      3. REST OF WORLD HUMAN GROWTH HORMONE MARKET CHALLENGES
      4. REST OF WORLD HUMAN GROWTH HORMONE MARKET REGULATORY FRAMEWORK
      5. KEY PLAYERS IN REST OF WORLD HUMAN GROWTH HORMONE MARKET
      6. REGIONAL ANALYSIS
        1. LATIN AMERICA
          1. LATIN AMERICA HUMAN GROWTH HORMONE MARKET SIZE & OPPORTUNITIES
        2. MIDDLE EAST & AFRICA
          1. MIDDLE EAST & AFRICA HUMAN GROWTH HORMONE MARKET SIZE & OPPORTUNITIES
  9. COMPETITIVE LANDSCAPE
    1. KEY STRATEGIC DEVELOPMENTS
      1. MERGERS & ACQUISITIONS
      2. PRODUCT LAUNCHES & DEVELOPMENTS
      3. PARTNERSHIPS & AGREEMENTS
      4. BUSINESS EXPANSIONS & DIVESTITURES
    2. COMPANY PROFILES
      1. ANKEBIO CO LTD
        1. COMPANY OVERVIEW
        2. PRODUCTS / SERVICES LIST
        3. STRENGTHS & CHALLENGES
      2. ELI LILY AND COMPANY
        1. COMPANY OVERVIEW
        2. PRODUCTS / SERVICES LIST
        3. STRENGTHS & CHALLENGES
      3. FERRING PHARMACEUTICALS
        1. COMPANY OVERVIEW
        2. PRODUCTS / SERVICES LIST
        3. STRENGTHS & CHALLENGES
      4. ISPEN
        1. COMPANY OVERVIEW
        2. PRODUCTS / SERVICES LIST
        3. STRENGTHS & CHALLENGES
      5. LG CHEM LTD
        1. COMPANY OVERVIEW
        2. PRODUCTS / SERVICES LIST
        3. STRENGTHS & CHALLENGES
      6. MERC & CO INC
        1. COMPANY OVERVIEW
        2. PRODUCTS / SERVICES LIST
        3. STRENGTHS & CHALLENGES
      7. NOVARTIS INTERNATIONAL AG
        1. COMPANY OVERVIEW
        2. PRODUCTS / SERVICES LIST
        3. STRENGTHS & CHALLENGES
      8. NOVO NORDISK AS 
        1. COMPANY OVERVIEW
        2. PRODUCTS / SERVICES LIST
        3. STRENGTHS & CHALLENGES
      9. PFIZER INC 
        1. COMPANY OVERVIEW
        2. PRODUCTS / SERVICES LIST
        3. STRENGTHS & CHALLENGES
      10. SANDOZ INTERNATIONAL GMBH
        1. COMPANY OVERVIEW
        2. PRODUCTS / SERVICES LIST
        3. STRENGTHS & CHALLENGES

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT – HUMAN GROWTH HORMONE 

TABLE 2: GLOBAL HUMAN GROWTH HORMONE MARKET, BY APPLICATION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 3: GLOBAL HUMAN GROWTH HORMONE MARKET, BY APPLICATION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 4: GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 5: GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 6: GLOBAL PRADER-WILLI SYNDROME MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 7: GLOBAL PRADER-WILLI SYNDROME MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 8: GLOBAL TURNER SYNDROME MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 9: GLOBAL TURNER SYNDROME MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 10: GLOBAL SMALL FOR GESTATIONAL AGE MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 11: GLOBAL SMALL FOR GESTATIONAL AGE MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 12: GLOBAL OTHER APPLICATIONS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 13: GLOBAL OTHER APPLICATIONS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 14: GLOBAL HUMAN GROWTH HORMONE MARKET, BY ROUTE OF ADMINISTRATION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 15: GLOBAL HUMAN GROWTH HORMONE MARKET, BY ROUTE OF ADMINISTRATION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 16: GLOBAL ORAL MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 17: GLOBAL ORAL MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 18: GLOBAL INTRAVENOUS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 19: GLOBAL INTRAVENOUS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 20: GLOBAL INTRAMUSCULAR MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 21: GLOBAL INTRAMUSCULAR MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 22: GLOBAL SUBCUTANEOUS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 23: GLOBAL SUBCUTANEOUS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 24: GLOBAL HUMAN GROWTH HORMONE MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 25: GLOBAL HUMAN GROWTH HORMONE MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 26: GLOBAL HOSPITAL PHARMACY MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 27: GLOBAL HOSPITAL PHARMACY MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 28: GLOBAL RETAIL PHARMACY MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 29: GLOBAL RETAIL PHARMACY MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 30: GLOBAL ONLINE PHARMACY MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 31: GLOBAL ONLINE PHARMACY MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 32: GLOBAL HUMAN GROWTH HORMONE MARKET, BY GEOGRAPHY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 33: GLOBAL HUMAN GROWTH HORMONE MARKET, BY GEOGRAPHY, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 34: NORTH AMERICA HUMAN GROWTH HORMONE MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 35: NORTH AMERICA HUMAN GROWTH HORMONE MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 36: NORTH AMERICA HUMAN GROWTH HORMONE MARKET REGULATORY FRAMEWORK

TABLE 37: KEY PLAYERS OPERATING IN NORTH AMERICA HUMAN GROWTH HORMONE MARKET

TABLE 38: EUROPE HUMAN GROWTH HORMONE MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION) 

TABLE 39: EUROPE HUMAN GROWTH HORMONE MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 40: EUROPE HUMAN GROWTH HORMONE MARKET REGULATORY FRAMEWORK

TABLE 41: KEY PLAYERS OPERATING IN EUROPE HUMAN GROWTH HORMONE MARKET

TABLE 42: ASIA-PACIFIC HUMAN GROWTH HORMONE MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 43: ASIA-PACIFIC HUMAN GROWTH HORMONE MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 44: ASIA-PACIFIC HUMAN GROWTH HORMONE MARKET REGULATORY FRAMEWORK

TABLE 45: KEY PLAYERS OPERATING IN ASIA-PACIFIC HUMAN GROWTH HORMONE MARKET

TABLE 46: REST OF WORLD HUMAN GROWTH HORMONE MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 47: REST OF WORLD HUMAN GROWTH HORMONE MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 48: REST OF WORLD HUMAN GROWTH HORMONE MARKET REGULATORY FRAMEWORK

TABLE 49: KEY PLAYERS OPERATING IN REST OF WORLD HUMAN GROWTH HORMONE MARKET

TABLE 50: LIST OF MERGERS & ACQUISITIONS

TABLE 51: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

TABLE 52: LIST OF PARTNERSHIPS & AGREEMENTS

TABLE 53: LIST OF BUSINESS EXPANSIONS & DIVESTITURES

LIST OF FIGURES 

FIGURE 1: KEY MARKET TRENDS

FIGURE 2: PORTER’S FIVE FORCES ANALYSIS

FIGURE 3: GROWTH PROSPECT MAPPING FOR UNITED STATES 

FIGURE 4: GROWTH PROSPECT MAPPING FOR GERMANY

FIGURE 5: GROWTH PROSPECT MAPPING FOR SOUTH KOREA

FIGURE 6: GROWTH PROSPECT MAPPING FOR SOUTH AFRICA

FIGURE 7: MARKET MATURITY ANALYSIS

FIGURE 8: MARKET CONCENTRATION ANALYSIS

FIGURE 9: GLOBAL HUMAN GROWTH HORMONE MARKET, GROWTH POTENTIAL, BY APPLICATION, IN 2022

FIGURE 10: GLOBAL HUMAN GROWTH HORMONE MARKET, BY GROWTH HORMONE DEFICIENCY, 2023-2032 (IN $ MILLION)

FIGURE 11: GLOBAL HUMAN GROWTH HORMONE MARKET, BY PRADER-WILLI SYNDROME (PWS), 2023-2032 (IN $ MILLION)

FIGURE 12: GLOBAL HUMAN GROWTH HORMONE MARKET, BY TURNER SYNDROME, 2023-2032 (IN $ MILLION)

FIGURE 13: GLOBAL HUMAN GROWTH HORMONE MARKET, BY SMALL FOR GESTATIONAL AGE (SGA), 2023-2032 (IN $ MILLION)

FIGURE 14: GLOBAL HUMAN GROWTH HORMONE MARKET, BY OTHER APPLICATION, 2023-2032 (IN $ MILLION)

FIGURE 15: GLOBAL HUMAN GROWTH HORMONE MARKET, GROWTH POTENTIAL, BY ROUTE OF ADMINISTRATION, IN 2022

FIGURE 16: GLOBAL HUMAN GROWTH HORMONE MARKET, BY ORAL, 2023-2032 (IN $ MILLION)

FIGURE 17: GLOBAL HUMAN GROWTH HORMONE MARKET, BY INTRAVENOUS, 2023-2032 (IN $ MILLION)

FIGURE 18: GLOBAL HUMAN GROWTH HORMONE MARKET, BY INTRAMUSCULAR, 2023-2032 (IN $ MILLION)

FIGURE 19: GLOBAL HUMAN GROWTH HORMONE MARKET, BY SUBCUTANEOUS, 2023-2032 (IN $ MILLION)

FIGURE 20: GLOBAL HUMAN GROWTH HORMONE MARKET, GROWTH POTENTIAL, BY DISTRIBUTION CHANNEL, IN 2022

FIGURE 21: GLOBAL HUMAN GROWTH HORMONE MARKET, BY HOSPITAL PHARMACY, 2023-2032 (IN $ MILLION)

FIGURE 22: GLOBAL HUMAN GROWTH HORMONE MARKET, BY RETAIL PHARMACY, 2023-2032 (IN $ MILLION)

FIGURE 23: GLOBAL HUMAN GROWTH HORMONE MARKET, BY ONLINE PHARMACY, 2023-2032 (IN $ MILLION)

FIGURE 24: NORTH AMERICA HUMAN GROWTH HORMONE MARKET, COUNTRY OUTLOOK, 2022 & 2032 (IN %)

FIGURE 25: UNITED STATES HUMAN GROWTH HORMONE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 26: CANADA HUMAN GROWTH HORMONE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 27: EUROPE HUMAN GROWTH HORMONE MARKET, COUNTRY OUTLOOK, 2022 & 2032 (IN %)

FIGURE 28: UNITED KINGDOM HUMAN GROWTH HORMONE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 29: GERMANY HUMAN GROWTH HORMONE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 30: FRANCE HUMAN GROWTH HORMONE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 31: ITALY HUMAN GROWTH HORMONE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 32: SPAIN HUMAN GROWTH HORMONE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 33: BELGIUM HUMAN GROWTH HORMONE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 34: POLAND HUMAN GROWTH HORMONE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 35: REST OF EUROPE HUMAN GROWTH HORMONE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 36: ASIA-PACIFIC HUMAN GROWTH HORMONE MARKET, COUNTRY OUTLOOK, 2022 & 2032 (IN %)

FIGURE 37: CHINA HUMAN GROWTH HORMONE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 38: JAPAN HUMAN GROWTH HORMONE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 39: INDIA HUMAN GROWTH HORMONE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 40: SOUTH KOREA HUMAN GROWTH HORMONE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 41: INDONESIA HUMAN GROWTH HORMONE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 42: THAILAND HUMAN GROWTH HORMONE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 43: VIETNAM HUMAN GROWTH HORMONE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 44: AUSTRALIA & NEW ZEALAND HUMAN GROWTH HORMONE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 45: REST OF ASIA-PACIFIC HUMAN GROWTH HORMONE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 46: REST OF WORLD HUMAN GROWTH HORMONE MARKET, REGIONAL OUTLOOK, 2022 & 2032 (IN %)

FIGURE 47: LATIN AMERICA HUMAN GROWTH HORMONE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 48: MIDDLE EAST & AFRICA HUMAN GROWTH HORMONE MARKET, 2023-2032 (IN $ MILLION)

FAQ’s

FAQs

The therapy can result in joint pains, acromegaly, diabetes, cardiovascular diseases, cancer, and other side effects.

The cost of human growth hormone therapy varies according to the type of HGH, the dosage, and the route of delivery.

HGH therapy insurance coverage varies based on the insurance company and the patient’s medical condition. Some insurance companies may cover human growth hormone therapy for specific illnesses, while others may not. It is critical to verify with your insurance provider to determine whether or not HGH therapy is covered.